HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Invites Pitches From Social Commerce Startups, Chasing ‘Mega-Trends Of The Future’

Executive Summary

Firm extends invitation to startups in livestream commerce, shoppable media, group buying, and gaming commerce to submit for the chance to pitch to Unilever beauty brands as part of the company’s Positive Beauty Growth Platform.

You may also be interested in...



Unilever Stepping Up Pricing To Offset Rising Costs While New Businesses Continue To Fuel Growth

“We are still managing in COVID times,” says CEO Alan Jope during Unilever’s 22 July call to discuss fiscal 2021 first-half results.

Personal Care News In Brief: Unilever Buys Korean Skin Care; P&G's Gillette Sues Edgewell/Schick; More

Corporation/startup collaborations have surpassed optional to become business-critical, according to a recent report from Unilever Foundry. Meanwhile, Unilever buys South Korea's third-largest cosmetics company for $2.7bil acquisition, and P&G's Gillette alleges that Edgewell Personal Care infringed its "removably attachable" razor cartridge patent with Schick Hydro Connect 5.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel